Research programme: protease inhibitors - Polyphor

Drug Profile

Research programme: protease inhibitors - Polyphor

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Polyphor
  • Class Peptides; Small molecules
  • Mechanism of Action Cysteine endopeptidase inhibitors; Leucocyte elastase inhibitors; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Alpha 1-antitrypsin deficiency; Chronic obstructive pulmonary disease; Cystic fibrosis
  • Discontinued Asthma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alpha-1-antitrypsin-deficiency in Switzerland (Inhalation, Aerosol)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in Switzerland (Inhalation, Aerosol)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cystic-fibrosis in Switzerland (Inhalation, Aerosol)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top